- Present in blood plasma, immunoglobulins help the immune system against certain diseases.
- The ANSM is concerned about the drastic drop in immunoglobulin stocks due to the Covid-19 pandemic.
From human plasma, immunoglobulins (ig) are essential proteins that circulate in our blood. With a broad spectrum of anti-IgG antibodies, they are essential for our immune system to fight infectious agents. They are particularly used to fight certain diseases, such as Guillain-Barré syndrome, Kawasaki disease or for the prophylaxis treatment of certain at-risk subjects exposed to a confirmed case of measles (unvaccinated pregnant woman with no history of measles, immunocompromised people or babies under 6 months whose mother has measles).
1,000 plasma donations are needed
Generally, this therapeutic product is prepared from plasma clusters from a minimum of 1,000 donations. But available stocks of immunoglobulins are declining at an alarming rate and struggling to replenish.
In a press release on Friday, October 15, the National Agency for the Safety of Medicines and Health Products (ANSM) is concerned about “Future strains in human immunoglobulins (Ig), after a reduction in the supply capacities of laboratories”.
According to the ANSM, “these tensions are explained in particular by the global drop in blood and plasma uptake in the context of Covid-19”.
Working groups on the issue
To think of ways to combat these supply difficulties, health authorities have announced that they have launched “working groups” which brings together representatives of patient associations and healthcare professionals. Two meetings have already been held on 30 September and 12 October. While waiting for a return to a normal supply of immunoglobulins, “all stakeholders recalled the importance of strict compliance” from “prioritization” diseases that can benefit from it “these essential medicines”.
It is not the first time that immunoglobulin stocks have been drastically reduced. Work has begun within the Ministry of Solidarity and Health “increase long-term plasma collection and thus optimize the security of supply of these treatments in France”, recalls the ANSM.